In-Office Application of AmnioAMP-MP: Technique and Dressing Protocol
The adoption of dehydrated human amniotic membrane (DHAM) allografts in office-based wound care settings has accelerated as clinicians seek effective biologic interventions that do not require operating room infrastructure, cold-chain logistics, or capital equipment investment. AmnioAMP-MP — a decellularized dehydrated human amniotic membrane processed via the proprietary PūrAMP Process and E-Beam sterilized to a sterility assurance level of 10⁻⁶ — is designed for ambient storage and point-of-care application, making it suitable for podiatry clinics, wound care centers, and satellite offices without ultralow-temperature freezer capacity.
Successful clinical outcomes with amniotic membrane allografts depend on more than product selection. Wound bed preparation, graft sizing and handling, fixation technique, secondary dressing selection, and structured follow-up each contribute independently to the biologic environment in which the allograft performs. Deviation from best practice at any step — incomplete debridement prior to application, incorrect dressing selection that desiccates the graft, or premature removal of the secondary dressing — can compromise healing trajectories regardless of the biologic quality of the graft itself.
This protocol provides an evidence-informed framework for in-office application of AmnioAMP-MP, organized sequentially from wound bed preparation through follow-up assessment. It is intended as an educational resource for podiatrists, wound care nurses, and office-based clinicians. All procedures should be performed in accordance with the manufacturer's Instructions for Use and the clinician's institutional protocols.
1. When In-Office Application Is Appropriate
AmnioAMP-MP is indicated for application to partial- and full-thickness acute and chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure injuries, surgical wounds, traumatic wounds, and wounds with exposed tendon, muscle, or bone (WoundReference). The product is regulated as a human cell, tissue, and cellular and tissue-based product (HCT/P) under Section 361 of the Public Health Service Act and 21 CFR 1271, intended for homologous use as a wound covering.
In-office application is appropriate when the following conditions are met:
- The wound bed is adequately vascularized (assessed by clinical examination for granulation tissue, bleeding on debridement, or confirmatory vascular studies) - Clinical infection is controlled or absent (no purulence, advancing erythema, or systemic signs of infection) - Necrotic burden has been adequately reduced through debridement - Adequate offloading is achievable (total contact cast, surgical shoe with relief insert, or equivalent for plantar wounds) - The patient can comply with scheduled follow-up visits
In-office application is not appropriate for wounds with uncontrolled deep-space infection, untreated osteomyelitis, active malignancy in the wound bed, or known hypersensitivity to amniotic membrane components. These are discussed further in the contraindications section.
2. Wound Bed Preparation
Wound bed preparation is the single most consequential step governing amniotic membrane allograft integration. The Wound Healing Society clinical practice guidelines identify adequate debridement as a foundational requirement for advanced wound biologic application — a graft placed on a necrotic, biofilm-colonized, or heavily exudative wound bed is functionally a biologic dressing discarded within days.
Debridement. Sharp debridement to a viable tissue base is the preferred method. Remove all necrotic tissue, fibrinous slough, and non-viable eschar to expose a granular, bleeding wound bed. The debridement endpoint is a wound bed composed of healthy granulation tissue without adherent biofilm or necrotic debris. For patients in whom sharp debridement is not tolerated or not clinically indicated (anticoagulated patients, ischemic wounds without adequate revascularization), alternative debridement modalities — enzymatic, autolytic, or mechanical — should be employed to achieve the same endpoint of a clean wound surface prior to graft application (Wound Healing Society Chronic Wound Care Guidelines; Journal of Wound Care Debridement Consensus). Biofilm reduction. Chronic wounds harbor biofilm in approximately 60 percent of cases, and biofilm presence is associated with delayed healing and reduced graft take (StatPearls, Wound Dressings). Wound cleansing with sterile saline or a surfactant-based wound cleanser immediately prior to graft placement is recommended. Povidone-iodine (Betadine) should be avoided — residual povidone-iodine is cytotoxic to granulation tissue and may interfere with graft adherence. Similarly, hydrogen peroxide and Dakin's solution (sodium hypochlorite) are cytotoxic and should not be used in the immediate pre-graft wound preparation step. Moisture balance. The wound bed should be moist but not macerated at the time of graft application. A heavily exudative wound should be managed with an absorbent primary dressing for one to two dressing-change cycles prior to graft application, to reduce exudate load to a manageable level. A desiccated wound bed should be hydrated with sterile saline immediately before graft placement; a dry wound bed inhibits graft adherence and rehydration of the dehydrated amniotic membrane sheet. Hemostasis. Active bleeding should be controlled prior to graft placement. A seroma or hematoma beneath the graft creates a physical barrier between the allograft and the wound bed, preventing ECM integration and paracrine signaling. Gentle pressure with saline-moistened gauze for one to two minutes is usually sufficient. Electrocautery, if required, should be used sparingly and only to cauterize discrete bleeding points; extensive thermal injury to the wound bed compromises the graft recipient site.3. Graft Sizing and Reconstitution
Sizing. AmnioAMP-MP is supplied in multiple sizes: 2×3 cm, 2×4 cm, 2×6 cm, 3×8 cm, 4×4 cm, and a 16 mm disk (WoundReference). The graft should be sized to cover the entire wound surface with the dehydrated sheet extending to the wound margins. Overlapping onto intact periwound skin by 1 to 2 mm is acceptable and may improve edge fixation, but significant overlap should be avoided — the graft provides biologic function only over the wound bed, and excess graft beyond the wound margins represents wasted product for which reimbursement is per square centimeter of wound area, not graft area.Wound surface area may be calculated using the ellipse formula (length × width × π/4) or by digital planimetry where available.
For wounds exceeding the size of a single available sheet, two or more sheets may be placed adjacent to each other, ensuring contact between adjacent graft edges. Do not overlap sheets — overlapping creates a double-thickness barrier that can delay host cell infiltration.
Reconstitution. Open the outer non-sterile pouch and transfer the inner sterile pouch to the sterile field. Remove the dehydrated graft sheet from the inner pouch and place it into a sterile basin containing room-temperature sterile saline. Rehydrate for 2 to 3 minutes — sufficient time for the sheet to become pliable and conformable without losing structural integrity. Do not soak for extended periods; prolonged immersion may leach matrix-bound growth factors that contribute to the graft's biologic activity.The rehydrated graft is translucent and handleable with sterile atraumatic forceps. It should be lifted gently — the rehydrated sheet is thinner and more delicate than the dry product — and transferred to the wound bed without folding or wringing, which can disrupt the collagen architecture.
4. Application Technique
AmnioAMP-MP may be applied via direct sheet placement to the wound bed. The decellularized, dehydrated sheet is non-side-specific after rehydration — either orientation may be placed in contact with the wound bed — though the stromal (collagen-rich) surface is conventionally oriented toward the wound to present the ECM scaffold to the recipient site.
Direct placement technique:1. Transfer the rehydrated sheet from the sterile saline basin to the wound bed using atraumatic forceps. 2. Position the sheet to cover the entire wound surface, ensuring contact with the wound margins. 3. Smooth the sheet gently with a saline-moistened cotton-tipped applicator or sterile gloved finger to eliminate air pockets or fluid collections between the graft and the wound bed. Air pockets create voids where the graft does not contact tissue and where seroma can accumulate. 4. If the wound bed has irregular contours, tunnels, or undermining, the sheet may be gently pressed into these spaces. The conformability of the rehydrated sheet allows it to drape into moderate contour variations without requiring sutures. 5. Do not suture or staple the graft to the wound bed. AmnioAMP-MP is not designed for suture fixation and the thin sheet does not retain sutures well. Fixation is achieved through the secondary dressing.
Alternative: Meshed application. For highly exudative wounds, the rehydrated sheet may be fenestrated with a sterile scalpel (3 to 5 small slits, each approximately 2 to 3 mm) to allow exudate drainage through the graft without compromising graft coverage. Exudate trapped beneath an intact sheet can lift the graft off the wound bed, preventing integration. Powder/particulate format note. AmnioAMP-MP is a sheet product, not a particulate or micronized format. The product is not designed for spray application, injection, or mixing into a slurry for wound packing. Application as an intact sheet preserves the ECM architecture that supports cellular attachment and proliferation.5. Secondary Dressing Selection
The secondary dressing serves three functions: graft fixation, moisture management, and protection from external contamination. Dressing selection is determined by wound exudate level, anatomic location, and planned wear time.
Non-adherent contact layer. A wide, non-adherent mesh or silicone contact layer (e.g., Mepitel, Adaptic, or equivalent) should be applied directly over the graft, extending 1 cm beyond the wound margins onto intact periwound skin. This layer protects the graft during dressing changes — removal of the secondary dressing does not disturb or lift the graft — and provides a fixation surface for tape or adhesive secondary dressings. Secondary dressing by exudate level:| Exudate Level | Dressing Type | Rationale | |---|---|---| | Dry to minimal | Hydrocolloid or thin foam | Maintains moist environment without maceration; hydrocolloid provides occlusion that supports autolytic debridement of residual non-viable tissue | | Moderate | Foam dressing (silicone-bordered) | Absorbs exudate while maintaining moist wound environment; silicone border provides atraumatic adhesion and seal | | Heavy | Calcium alginate or hydrofiber beneath foam | Alginate/hydrofiber absorbs high-volume exudate and converts to gel, protecting graft; overlying foam provides secondary absorption and fixation |
Offloading. For plantar diabetic foot ulcers, a total contact cast, removable cast walker rendered irremovable, or surgical shoe with multi-density insert is required. Offloading is not optional — the Wound Healing Society guidelines and the International Working Group on the Diabetic Foot both identify adequate offloading as essential to healing outcomes with advanced wound biologics. A perfectly applied amniotic membrane graft on a plantar surface that receives full weight-bearing pressure will fail regardless of graft quality. Dressing change schedule. The secondary dressing (foam, alginate, or hydrocolloid) should be changed per its own wear-time guidelines — typically every 2 to 3 days for foam and every 1 to 2 days for alginate when exudate is heavy, or every 5 to 7 days for hydrocolloid on low-exudate wounds. The non-adherent contact layer should be left in place and not disturbed at each outer dressing change unless there are clinical signs of infection, excessive exudate accumulation, or loss of graft adherence.The graft itself is not removed. Unlike traditional wound dressings that are discarded at each change, AmnioAMP-MP is a bioresorbable scaffold — it integrates into the wound bed over the course of days to weeks and is not manually removed. The product is re-applied at weekly intervals or at the clinician's discretion based on wound assessment.
6. Follow-Up Assessment Protocol
Structured follow-up at defined intervals allows the clinician to assess graft integration, identify early signs of failure or infection, and determine the need for reapplication.
Week 1 (Day 5–7). First post-application assessment. Remove all dressings down to the non-adherent contact layer. Gently lift the contact layer to inspect the graft site. Expected findings: the graft should appear as a translucent, integrated film over the wound bed. Partial graft retention is common — areas of graft loss correspond to areas of high exudate, shear, or suboptimal wound bed preparation. Assess for:- Percentage graft take (visual estimate) - Signs of infection (erythema beyond wound margin, purulence, odor, increasing pain) - Exudate level and character - Periwound skin condition (maceration, dermatitis)
If graft take is adequate and no signs of infection are present, reapply non-adherent contact layer and secondary dressing. Reapplication of AmnioAMP-MP is indicated if graft take is less than 50 percent or if areas of the wound bed are exposed without graft coverage.
Week 2 (Day 12–14). Second assessment. By this interval, the wound should demonstrate measurable reduction in surface area or volume if the graft is integrating properly. Expected findings: wound edge contraction, islands of epithelialization at wound margins, and graft degradation with replacement by host granulation tissue. Document wound measurements (length, width, depth), photograph, and assess for interval change.Reapplication is common at this visit — many chronic wounds require two to three weekly applications to achieve full wound bed coverage with integrated ECM scaffold. CMS Medicare Administrative Contractors generally allow weekly application at carrier discretion, and multiple applications are standard in published amniotic membrane protocols.
Week 4 (Day 26–30). Formal reassessment point. By week 4, a wound that is responding to amniotic membrane therapy should demonstrate at least 40 to 50 percent reduction in wound surface area compared to baseline — a validated prognostic indicator for eventual complete closure. Wounds that have not achieved this threshold should trigger a reassessment of:- Vascular status (repeat ABI/toe pressures, consider arterial duplex) - Infection status (deep tissue culture if indicated; consider plain films or MRI for osteomyelitis) - Offloading adequacy - Nutritional status (prealbumin, albumin) - Comorbid disease optimization (HbA1c, edema management for venous wounds)
7. Contraindications and Escalation Criteria
Absolute contraindications: Known hypersensitivity to amniotic membrane or any component of the product; application to a clinically infected wound bed without prior infection control; untreated osteomyelitis in the wound base; active malignancy in the wound; application to a non-viable wound bed (dry eschar with no bleeding on debridement in an ischemic limb without revascularization). Relative contraindications: Uncontrolled diabetes (HbA1c >12 percent); severe peripheral arterial disease without planned revascularization (ABI <0.5 or toe pressure <30 mmHg); patient inability to comply with offloading; concurrent systemic immunosuppression that would be expected to impair wound healing. Escalation criteria — scenarios that should prompt referral to a surgical wound specialist or multidisciplinary wound center:- Failure to achieve 40 percent wound area reduction at 4 weeks - Progressive wound deterioration despite two or more graft applications - Development of deep-space infection, abscess, or osteomyelitis - Wound exposure of vital structures (major vessels, joint capsule) - Clinical suspicion of malignancy (Marjolin ulcer in a long-standing wound) - Wounds in patients with scleroderma, active vasculitis, or pyoderma gangrenosum, where wound bed preparation and graft integration may be complicated by the underlying disease process
8. Summary
In-office application of AmnioAMP-MP follows a structured sequence: wound bed preparation through adequate debridement and biofilm reduction, graft sizing to wound dimensions, rehydration and atraumatic placement, fixation via a non-adherent contact layer, secondary dressing selection based on exudate level, offloading where applicable, and scheduled follow-up assessment at weeks 1, 2, and 4. Each step in the sequence contributes to the biologic environment in which the allograft integrates with host tissue.
The protocol is designed for the operational realities of office-based wound care: no freezer, no thawing, no capital equipment, and a procedure time that fits within a standard clinic visit. The ambient storage, 2-to-3-minute rehydration, and non-suture fixation of AmnioAMP-MP support this workflow without requiring operating room resources.
Clinicians should note that the evidence base for amniotic membrane application technique remains predominantly consensus- and experience-driven rather than RCT-comparative. While the biologic rationale for each protocol step is well-supported — debridement, moisture balance, exudate management, and offloading are bedrock principles of wound care supported by the Wound Healing Society guidelines, the International Working Group on the Diabetic Foot, and the StatPearls wound dressing framework — few published studies directly compare, for example, one secondary dressing type to another specifically over amniotic membrane allografts. Clinicians should apply their clinical judgment, manufacturer IFU guidance, and institutional protocols to adapt this framework to individual patient presentations.
---
Disclaimer: This protocol is for educational purposes and is not a substitute for clinical judgment, manufacturer Instructions for Use, or institutional protocols. Individual patient outcomes vary. No outcome is guaranteed. AmnioAMP-MP is regulated as an HCT/P under Section 361 of the Public Health Service Act and 21 CFR 1271 for homologous use. Reimbursement amounts referenced reflect CMS CY 2026 policy effective January 1, 2026; clinicians should verify current coverage and payment rates with their local Medicare Administrative Contractor or commercial payer before billing. Products discussed are decellularized, dehydrated, and non-viable; no living cell claims are made. Sources:- WoundReference — AmnioAMP-MP product profile: indications, sizes, HCPCS Q4250, regulatory pathway - StatPearls [Internet], NCBI Bookshelf — Wound Dressings (Britto EJ, Nezwek TA, Popowicz P, Robins M; last update January 23, 2024) - StatPearls [Internet], NCBI Bookshelf — Amniotic Membrane Graft: preparation, storage, indications, and technique - Wound Healing Society — Chronic Wound Care Guidelines; Acute Wound Care Guidelines (woundheal.org) - Journal of Wound Care — Best Practice for Wound Debridement: Consensus Document (Debridement Consensus Panel) - International Working Group on the Diabetic Foot (IWGDF) — Guidelines on offloading and wound management in diabetic foot disease - PubMed / PMC — Amniotic Membrane Transplantation for Wound Healing, Tissue Regeneration and Immune Modulation (PMC12316762) - CMS CY 2026 Physician Fee Schedule Final Rule — Skin Substitute Payment Methodology (effective January 1, 2026) - AMA CPT 2026 — Skin Substitute Graft Application Codes 15271–15278